Those medical devices include syringes, needles and IV catheters. The Franklin Lakes, New Jersey-based company aims to meet the ongoing needs of the nation’s healthcare system.
This uptick in manufacturing follows last year’s capacity increase after the FDA issued warnings related to syringes manufactured in China. The company said it comes as part of its 2024 investment of more than $10 million to expand manufacturing capacity. BD installed new needle and syringe production lines at plants in Connecticut and Nebraska. One is already fully operational and the company expects additional lines to start up in the coming months.
BD expects its new manufacturing lines to boost its capacity of domestically manufactured, safety-engineered injection devices by more than 40%, with conventional syringes increasing by more than 50%. This adds hundreds of millions of units annually to support U.S. healthcare delivery. That extends to hospital procedures, vaccinations, medication preparation and drug delivery to patients.
According to BD, the increased capacity adds more than 215 full-time employees at the Nebraska and Connecticut facilities. The company also plans to invest more than $30 million in 2025 to expand manufacturing capacity for IV lines at its Utah plant. This further supports growth in catheter solutions. The company already put more than $2 million toward IV line improvements in 2024.
“Domestic manufacturing is crucial for ensuring a resilient supply of essential health care devices,” said Eric Borin, president of Medication Delivery Solutions at BD. “By expanding our production capacity, we are not only meeting the critical needs of patients and providers, but we also are reinforcing our commitment to the nation’s health care infrastructure.”
